CapeRay’s patented technology combines two breast imaging modalities within the same device, thus enabling both sets of images to be acquired simultaneously.
Cape Town, South Africa, 30 January 2018.
A novel breast imaging system, designed for the early detection of cancer in women with dense breast tissue, has just been launched. CapeRay’s patented technology combines two breast imaging modalities within the same device, thus enabling both sets of images to be acquired simultaneously.
“This is the world’s first such commercial system,” said Dr Kit Vaughan, CEO of CapeRay. “By integrating full-field digital mammography (FFDM) and automated breast ultrasound (ABUS) in a single platform, we are providing clinicians with a screening tool that will significantly enhance their diagnostic success.” The Aceso system has three primary advantages over separate FFDM and ABUS systems: (1) it takes less than 10 minutes to acquire a full set of images, compared with 20 to 30 minutes; (2) the breast is in the identical orientation and degree of compression, enabling fusion of the two imaging modalities; and (3) the cost of Aceso is significantly less.
Dr Kamila Padia, head of radiology at 2 Military Hospital in Cape Town and principal author of a key paper published in Diagnostics in 2017, commented: “False negative findings [in mammography] can be devastating for the women concerned because a later diagnosis may lead to a poor prognosis and more expensive treatment. We believe that this secondgeneration Aceso system, with its improved quality FFDM and ABUS images, has demonstrated its potential for the early detection of breast cancer in busy clinics.”
CapeRay is also launching the AcesoFusion Diagnostic Viewing Station which is built on: two high-resolution monochrome monitors; an Apple Mac Mini computer; OsiriX MD software which has both the CE Mark and FDA approval; and the customised AcesoFusion plug-in that enables fusion of the FFDM and ABUS images that are in DICOM format.
Having secured the CE Mark for Aceso in Q4 of 2017, CapeRay’s management team will now seek FDA approval for Aceso, with a target date set for Q4 of 2018.
About Aceso: Named after the Greek goddess of healing, Aceso has been successfully tested in two separate clinical trials, in May 2014 and then in November 2015. These studies led to journal publications, first in Clinical Imaging in 2016, and more recently in Diagnostics, with a review article published in Diagnostic Imaging Europe in October 2017.
About CapeRay Medical: Located in Cape Town, South Africa, CapeRay is the innovative medical device company that has imagined, engineered and commercialised Aceso. The company first secured ISO 13485 certification in mid-2012 and since that time has been working steadfastly to bring its Aceso system to market. For further information about the ground-breaking Aceso system or the company, please visit http://www.caperay.com.
